The presence of EGFR mutations has been proposed as a crucial determinant of prognosis in individuals with NSCLC (Wu et al., 2010; Choi et al., 2012; Deng et al., 2021), but the predictive significance of EGFR mutations in NSCLC patients remains controversial (Zhang et al., 2014; Lin et al., 2017). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.